Triple

Target class: riluzole-containing product
Context triple: [Rilutek, instanceOf, riluzole-containing product]

• A. multiple sclerosis medication
  A multiple sclerosis medication is a drug or therapeutic agent designed to modify the disease course, manage relapses, or alleviate symptoms in individuals with multiple sclerosis by targeting immune or neurological processes.
• B. pegylated interferon beta-1a
  Pegylated interferon beta-1a is a long-acting, pegylated form of interferon used as a disease-modifying therapy to reduce relapses and slow progression in patients with relapsing forms of multiple sclerosis.
• C. Alzheimer’s disease drug
  An Alzheimer’s disease drug is a pharmacological agent designed to prevent, slow, or alleviate the cognitive and functional decline associated with Alzheimer’s pathology, typically by targeting amyloid, tau, neurotransmitter systems, or related neurodegenerative mechanisms.
• D. brand name drug chosen
  A brand name drug is a medication marketed under a proprietary, trademarked name by a specific pharmaceutical company, typically protected by patents and distinct from its generic equivalents.
• E. cholinesterase inhibitor
  A cholinesterase inhibitor is a substance that prevents the breakdown of the neurotransmitter acetylcholine by inhibiting cholinesterase enzymes, thereby enhancing cholinergic signaling in the nervous system.
• F. None of above.